Helus Pharma Appoints Neuroscience Veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs
Helus Pharma's appointment of Dr. Ken Kramer, a 20-year neuroscience medical affairs leader, strengthens the company's clinical development capabilities for its novel serotonergic agonists targeting depression and anxiety disorders.
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists, has appointed Dr. Ken Kramer as senior vice president of medical affairs. The appointment, effective immediately, brings more than 20 years of neuroscience-focused medical affairs leadership to the company, including experience at Bristol Myers Squibb, Karuna Therapeutics and AbbVie.
The company stated that Kramer is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders. Helus Pharma, the commercial operating name of Cybin Inc., is developing proprietary synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address unmet needs for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma is currently developing HLP003, a proprietary novel serotonergic agonist in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. This candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004, another proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder, with an extensive research portfolio of investigational compounds.
The appointment comes as the company seeks to improve the treatment landscape through the introduction of novel serotonergic agonists that aim to provide durable improvements in mental health. With class-leading data, Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. For company updates and more information about Helus Pharma, visit https://www.helus.com.
The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. This appointment represents a strategic move to bolster the company's medical affairs capabilities during critical late-stage clinical development phases for its lead candidates targeting significant mental health conditions.